Overview
Bioresearch Pharma is a company that repurposes existing topical drugs for dermatological applications, focusing on conditions such as androgenetic alopecia and psoriasis. They offer BRP-011, a therapy aimed at promoting hair growth, and BRP-007, a new treatment for plaque psoriasis with a unique mechanism of action. The company develops advanced medicines by utilizing well-tested therapeutic substances for new indications and creating novel drug formulations.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2022-03-09. Active
54 1020 1169 0000 8502 0878 7840- 80 1020 1169 0000 8502 0805 1239
- 87 1020 1169 0000 8702 0889 0065
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Mar 22, 2024 | Transformation |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Nov 25, 2025 | Aid for SMEs for innovation support | $1.5M$1,506,775 | Prezes Banku Gospodarstwa Krajowego |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
In the case of a one-person management board, the sole member of the management board is entitled to independently represent the company. In the case of a multi-member management board, representation of the company requires the joint action of two members of the management board or one member of the management board jointly with a commercial proxy.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Danuta Popinigis (69)  | Uprawnienia pośrednie: danuta popinigis sprawuje kontrolę nad bezpośrednim akcjonariuszem spółki, tj. fundacją rodzinną manawa w której jestbeneficjentem fundacji rodzinnej. manawa fundacja rodzinne posiada 43,24% akcji społki brp s.a. | |
Małgorzata Katarzyna Popinigis (42) | Uprawnienia pośrednie: danuta popinigis sprawuje kontrolę nad bezpośrednim akcjonariuszem spółki, tj. fundacją rodzinną manawa w której jest beneficjentem fundacji rodzinnej. manawa fundacja rodzinne posiada 43,24% akcji społki brp s.a. | |
Marian Popinigis (69) | Uprawnienia pośrednie: marian popinigis sprawuje kontrolę nad bezpośrednim akcjonariuszem spółki, tj. fundacją rodzinną manawa w której pełni funkcję prezesa jednoosobowego zarządu i jednocześnie jest fundatorem fundacji rodzinnej. manawa fundacja rodzinne posiada 43,24% akcji społki brp s.a. |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Pexon Polandsp. z o.o. | $122,615.96 | pexon.pl | ||
| Xenira Pharmaceuticalssp. z o.o. | $26,670.82 | xenirapharma.com | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com |
Change history
| Date | Event | |
|---|---|---|
| 2024-10-18 | Share capital change (168,190.00 PLN → 228,989.80 PLN) | |
| 2024-05-07 | Share capital change (162,500.00 PLN → 168,190.00 PLN) | |
| 2024-03-14 | Entered in the register |
FAQ
Last updated: 2026-07-21